SIGA Technologies, Inc.

Case No. 14-12623·New York Southern·Petition date Sep 16, 2014

Research this case Track this case Sign in

OverviewProfessionals

Cases

CourtFilingsPetition dateMore filters

Case

Funded debt

Stage

Exit

Next hearing

Last activity

Petition date

Court

SIGA Technologies, Inc. Professionals

SIGA Technologies, Inc.

Case No. 14-12623·New York Southern·Petition date Sep 16, 2014

Research this case Track this case Sign in

OverviewProfessionals

Professionals

Retained professionals and compensation participants, joined to their source filings.

AlixPartners, LLP

Fee applicant

Guggenheim Securities

Retained · fee applicantInvestment Banker · Creditors' committee

Dkt. 292
Dkt. 321
Dkt. 294
Dkt. 293

Herbert Smith Freehills Kramer

Fee applicant

PricewaterhouseCoopers LLP

Fee applicant

Prime Clerk LLC

Fee applicant

Proskauer Rose LLP

Fee applicant

Ressler & Ressler

Fee applicant

Susman Godfrey LLP

Fee applicant

Weil, Gotshal & Manges LLP

Fee applicant

Judge: Sean H. Lane
Petition assets: $100M–$500M
Petition liabilities: $100M–$500M
Industry: Healthcare

SIGA Technologies, Inc. is a New York City-based publicly traded biotech/pharmaceutical company incorporated in 1995 that develops medical countermeasures against serious biothreats. Its lead product, Tecovirimat, is a patented smallpox antiviral with FDA fast-track status, supplied to the U.S. Strategic Stockpile under a $463 million BARDA contract to deliver 2 million treatment courses under Project BioShield. R&D operations are based in Corvallis, Oregon. SIGA employs approximately 35 people and counts MacAndrews & Forbes Holdings Inc. as its largest indirect shareholder.

Case background, summaries, and key terms are generated from the filings on this docket. Docket entries and documents come from the court.

Report a data error